Am J Transplant, Volume 18, Suppl 3 Archives - Page 182 of 211 - ATC Abstracts

2018 American Transplant Congress
The Risk Factors of Acute Rejection in Patients with BK Nephropathy after the Reduction of Immunosuppression
C. Baek,¹ H. Kim,¹ W. Yang,¹ D. Han,² S-.K. Park.¹
¹Department of Internal Medicine, Division of Nephrology, Asan Medical Center, Seoul, Republic of Korea; ²Department of Surgery, Asan Medical Center, Seoul, Republic of Korea.
Background: BK nephropathy (BKN) affects graft function and increases the risk of graft failure. The reduction of immunosuppression is the main treatment for BKN. However,…
2018 American Transplant Congress
Cost Effectiveness of Lifelong Medicare Immunosuppressant Drug Coverage for Kidney Transplant Recipients in the Current Era
M. Kadatz,¹ J. Gill,² J. Gill,² K. Scott.³
¹Clinician Investigator Program, University of British Columbia, Vancouver, BC, Canada; ²Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada; ³Division of Nephrology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
While there is no Medicare time limit for dialysis patients, kidney transplant recipients lose their Medicare coverage 36 months after they receive their transplant. The…
2018 American Transplant Congress
Recipient IFNAR1 Signaling Supports Costimulation Independent Rejection by Promoting T Cell Activation
D. Mathews, A. Ghosh, Y. Dong, K. Polireddy, A. Stephenson, C. Breeden, Y. Liu, A. Adams.
Department of Surgery, Emory University, Atlanta, GA.
Costimulation blockade (CoB) is a promising strategy for more targeted/less toxic transplant immunosuppression which has led to the first improvement in long-term outcomes for transplant…
2018 American Transplant Congress
Curative Correction of FAH Deficiency by Chimeric Stem Cells Transplantation
D. Joo,^1,2 E. Nelson,¹ Y. Zhang,¹ B. Amiot,¹ S. Ho,³ C. Lancto,⁴ D. Carlson,⁴ L. Queiroz,⁵ S. Nyberg.¹
¹Division of Transplant Surgery, Mayo Clinic, Rochester, MN; ²Department of Surgery, Yonsei University College of Medicine, Seoul, Korea; ³Department of Pathology, University of Michigan, Ann Arbor, MI; ⁴Recombinetics Inc, Saint Paul, MN; ⁵International Center for Biotechnology, Cooperative Resources International, Mount Horeb, WI.
Fumarylacetoacetate hydrolase (FAH) deficient pigs have been proposed as surrogate hosts for large scale in vivo expansion of normal FAH+ hepatocytes. However, immunologic rejection prevents…
2018 American Transplant Congress
Follow Up of Patients Treated with the IgG Endopeptidase (IdeS) for Desensitization and HLA Incompatible (HLAi) Kidney Transplantation
S. Jordan,¹ J. Choi,¹ E. Huang,¹ R. Najjar,¹ A. Peng,¹ X. Zhang,¹ S. Louie,¹ M. Haas,² S. Sethi,¹ I. Kim,¹ A. Vo.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction:Donor-specific antibodies (DSAs) create an immunologic barrier to transplantation. This prevents transplantation for a significant percentage of highly-HLA sensitized patients (HS). Current desensitization therapies are…
2018 American Transplant Congress
Impact of Center Volume on Kidney Transplant Outcomes in Contemporary U.S. Transplant Practice
T. Alhamad,¹ F. Abbas,¹ D. Brennan,² A. Malone,¹ J. Wellen,¹ R. Delos Santos,¹ A. Khan,¹ J. Li,¹ R. Rattanavich,¹ K. Lentine.³
¹Washington University, St. Louis; ²Johns Hopkins University, Baltimore; ³Saint Louis University, St. Louis.
With the significant organ shortage, transplant professionals have expanded use of higher-risk deceased donor organs. The use of such organs requires surgical expertise and multidisciplinary…
2018 American Transplant Congress
Effect of HLA Antibodies on Graft Survival in Adult Live Donor Liver Transplantation
M. Simpson,¹ M. Akoad,¹ F. Gordon,¹ Y-.L. Cheah,¹ C. Simon,¹ J. Pomposelli,² E. Pomfret.²
¹Transplantation, Lahey Hospital & Medical Center, Burlington, MA; ²Transplantation, University of Colorado Medical Center, Aurora, CO.
The relevance of HLA antibodies in liver transplantation is currently being re-evaluated. While hyperacute rejections are not an issue, antibody effects on long-term outcomes are…
2018 American Transplant Congress
Medical Crowdfunding for Organ Transplant Patients
W. Durand,¹ J. Peters,¹ A. Eltorai,¹ S. Kalagara,¹ A. Osband,² A. Daniels.³
¹Alpert Medical School, Brown University, Providence, RI; ²Division of Transplant Surgery, Department of Surgery, Alpert Medical School, Brown University, Providence, RI; ³Division of Spine Surgery, Department of Orthopaedics, Alpert Medical School, Brown University, Providence, RI.
BACKGROUND: An increasing number of patients and families are utilizing online crowdfunding to support their medical expenses related to organ transplantation. The factors that influence…
2018 American Transplant Congress
PD-L1 May Serve as a Biomarker for Chimerism-Induced Tolerance in Kidney Transplant Recipients
A. Merchak,¹ A. Khalil,¹ A. Chhabra,¹ J. Leventhal,² S. Ildstad.¹
¹University of Louisville, Louisville, KY; ²Northwestern Memorial Hospital, Chicago, IL.
Durable chimerism is currently the most reliable biomarker of donor specific tolerance. Identifying and validating other predictive biomarkers is therefore a high priority. Since 2009…
2018 American Transplant Congress
Offspring Living Kidney Donors Should Not Be Ruled Out
X. Luo, A. Massie, C. Holscher, D. Segev.
Johns Hopkins University, Baltimore.
A recent study (AJT, January 2018) suggested that kidneys from offspring live donors conferred worse post-transplant outcomes than non-offspring live donors, and advocated selecting non-offspring…